SIRPA and neoplasm: The efficacy of SIRP-α inhibitors alone may be limited; however, their combination with antibodies that target various tumor antigens could result in enhanced anti-tumor effects, thereby broadening the scope of anti-SIRP-α cancer immunotherapy.